News Releases

- Up to $15 million available in three $5 million tranches; additional $25 million potentially available - VANCOUVER, Aug. 22, 2018 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage...

- More than 1,200 patients treated to date with momelotinib, including in two Phase 3 trials; ongoing therapy for more than seven years in some patients - - Demonstrated meaningful anemia-related...

- SRA737 Monotherapy trial prioritized for ovarian cancer; targeting enrollment of 65 patients with preliminary data anticipated in H1 2019 - - SRA737 LDG Combination trial to be amended and...

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with...

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with...

- SRA737 Monotherapy Phase 1/2 trial expanded to enroll CCNE1-driven ovarian cancer cohort - - SRA737 Low-Dose Gemcitabine Combination Phase 1/2 trial advanced into cohort expansion phase - -...

- Two posters reporting activity for SRA737 with PARPi (in CCNE1-driven cancers, HRR proficient cancers, and PARPi-resistant cancers) reinforce the potential broad clinical utility of this...

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with...

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with...

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer,...

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer,...

- Janssen supply agreement for ZEJULA® (niraparib) facilitates novel PARPi combination trial with SRA737 in prostate cancer - - SRA737 clinical development program significantly expanded - -...

- Ongoing SRA737 clinical studies expanded to target aggregate enrollment of 200 patients across ten cancer indications – - Adding new SRA737 monotherapy cohort for CCNE1-driven ovarian cancer -...

- Janssen to supply PARP inhibitor niraparib for Sierra's Phase 1b/2 combination trial with Chk1 inhibitor SRA737 - VANCOUVER, Feb. 27, 2018 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a...

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with...

- Sierra also to present at the BIO CEO & Investor Conference in New York on February 12th - VANCOUVER, Feb. 6, 2018 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development...

- "Leveraging Synthetic Lethality to Enhance Clinical Trials with SRA737, a Next-Generation Chk1 Inhibitor" scheduled for 2:15 pm ET on February 1, 2018 in Boston - VANCOUVER, Jan. 29, 2018 /CNW/...

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with...

- Chk1 inhibitor SRA737 Monotherapy trial expanded to eight leading centers across the UK - - On track to provide planned SRA737 Program Update in February 2018 - - $107.8 million cash expected to...

- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 4:00 p.m. GMT on November 16, 2017 - VANCOUVER, Nov. 7, 2017 /CNW/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug...

- SRA737 demonstrates synergy with replication stress-inducing agents - - SRA737 plus gemcitabine efficacious in gemcitabine-resistant tumor models - - SRA737 potentiated by novel sub-therapeutic...

- Dr. Allen, key contributor in the advancement of PARP inhibitors, to support Sierra in developing next-generation DDR therapeutics - VANCOUVER, Oct. 25, 2017 /CNW/ - Sierra Oncology, Inc....

- Chk1 inhibitor SRA737 demonstrates chemical synthetic lethality with replication stress-inducing agents, including potentiation by novel low-dose gemcitabine combination, in preclinical models...

- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 11:00 am PT on October 17, 2017 - VANCOUVER, Oct 11, 2017 /CNW/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug...

- Dr. Leonard Post, Dr. Eric J. Brown, and Dr. Geoffrey I. Shapiro to discuss DDR scientific and clinical development - VANCOUVER, Oct. 4, 2017 /CNW/ - Sierra Oncology, Inc. (SRRA), a clinical...

- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 8:35 am ET on September 26, 2017 - VANCOUVER, Sept. 20, 2017 /CNW/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug...

Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today...

- Leading experts in DDR biology, chemistry and medicine to help maximize the potential clinical and commercial opportunities for Sierra's drug candidates – VANCOUVER, Aug. 15, 2017 /CNW/ -...

- On track to provide preliminary update from Chk1 inhibitor SRA737 clinical trials in early 2018 - - Phase 1 trials amended and enhanced to prospectively enroll patients with genetically-defined...

- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 1:55 pm ET on August 15, 2017 - VANCOUVER, Aug. 2, 2017 /CNW/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug...

- Presenting two posters describing innovative trial designs leveraging Chk1 synthetic lethality at the ASCO 2017 Annual Meeting - VANCOUVER, June 5, 2017 /CNW/ - Sierra Oncology, Inc. (NASDAQ:...

- Selection patent issued for SRA737 covers the compound explicitly and extends initial protection out to 2033 - VANCOUVER, May 30, 2017 /CNW/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical...

- Company also to present at Jefferies Healthcare Conference at 2pm ET on June 8th - VANCOUVER, May 24, 2017 /CNW/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company...

- Phase 1 monotherapy and combination clinical trials amended to focus on novel genetically-driven, prospective patient selection strategy designed to demonstrate synthetic lethality - VANCOUVER,...

- Sierra ends Q1 with $125M to fund current operating plans through approximately mid-2019 - - Amendments to ongoing Phase 1 studies submitted to prospectively enroll patients with...

- Research conducted by Professor Paul Workman supports the use of SRA737 in certain genetically defined tumors and in combination with chemotherapy - VANCOUVER, April 3, 2017 /CNW/ - Sierra...

Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer,...

Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer,...

Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer,...

- Company plans to study synthetic lethality in genetically-defined patient cohorts - - Preclinical research underway studying DDR and immuno-oncology combinations - VANCOUVER, Jan. 9, 2017 /CNW/...

- Sierra Oncology to trade on NASDAQ under the symbol 'SRRA' - - Company to present at the BIOTECH Showcase in San Francisco on January 11th - VANCOUVER, Jan. 9, 2017 /CNW/ - ProNAi Therapeutics,...

- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 8:00 am on November 17th, 2016 - VANCOUVER, Nov 14, 2016 /CNW/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage drug...

ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with cancer, today reported its...

- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 9:00 am on October 19th, 2016 - VANCOUVER, Oct. 13, 2016 /CNW/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage drug...

- PNT737 currently in Phase 1 clinical trials at the Royal Marsden, London, UK - - Potential to exploit cancer-driving genetic mutations to achieve synthetic lethality - - Broad development...

ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a drug development company focused on advancing targeted therapeutics for the treatment of patients with cancer, today reported its financial and...

ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a drug development company advancing targeted therapeutics for patients with cancer, today announced interim results from the Wolverine Phase 2 trial of...

ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company advancing novel targeted therapeutics, today announced it has appointed Dr. Christian Hassig as Senior Vice President,...

- Small molecule kinase inhibitor AS-141 positioned for clinical trials in 2017 - - CDC7 is an important regulator of DNA replication and DNA damage response - VANCOUVER, May 26, 2016 /CNW/ -...

- ProNAi to hold Analyst & Investor Event at 7:00am CT on June 6th - - ProNAi to Present at Jefferies 2016 Healthcare Conference in New York on June 9th – VANCOUVER, May 18, 2016 /CNW/ - ProNAi...